+++
title = "Pfizer accused of pandemic profiteering as profits double"
description = "Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill"
date = "2022-02-09 19:11:04"
slug = "620411a27dc2ee05167d53a8"
image = "https://i.imgur.com/8vLghjX.jpg"
score = "2536"
categories = ['double', 'covid', 'profits']
+++

Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill

## Highlights

- Pfizer forecast another bumper year in 2022, with a big boost coming from its Covid-19 pill Paxlovid.
- The US drugmaker's overall revenues in 2021 doubled to $81.3bn.
- The bumper sales prompted accusations from campaigners of ‘pandemic profiteering’ The group Global Justice Now said the annual revenue of $81bn was more than the GDP of most countries.
- The group accused Pfizer of “ripping off public health systems’s money from money from the vaccine monopoly.
- It has charged the NHS £2.8bn above production cost for the 189m doses of the next dose of the vaccine.

---

{{< rawhtml >}}
  <p class="article-category">
    <a target="_blank" href="https://www.theguardian.com/business/2022/feb/08/pfizer-covid-vaccine-pill-profits-sales">READ THE ORIGINAL ARTICLE</a>
  </p>
{{< /rawhtml >}}
